Apolomics Inc. (APLMW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
APLMW Chart
People also search for
Apolomics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 506,289 | $13,163.51 | $7,746.22 | -$5,417.29 | -41.15% |
Apolomics Inc. (APLMW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Apolomics Inc. ever had a stock split?
Apolomics Inc. Profile
| Industrial Conglomerates Industry | Industrials Sector | Hung-Wen Chen CEO | NASDAQ (CM) Exchange | G0411D115 CUSIP |
| US Country | 14 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Apollomics, Inc. is a dynamic force in the biotechnology landscape, specializing in the groundbreaking area of oncology therapy research and development. Founded in 2015 by visionaries Liang Yu Guo and Sanjeev Redkar, the company has swiftly moved to the forefront of clinical-stage biotechnology, focusing its efforts on innovating treatments for cancer. With its headquarters in Foster City, California, Apollomics is committed to fulfilling the pressing need for more effective cancer therapies, utilizing cutting-edge science to bring hope to patients facing dire diagnoses.
Products and Services
- Oncology Therapies Development
At the heart of Apollomics' mission is the development of novel oncology therapies. By strategically targeting the most challenging unmet medical needs within the cancer treatment landscape, the company is dedicated to engineering innovative drugs. Their pipeline represents a beacon of hope, aiming to transform the therapeutic landscape through advances in science and medicine.
